Overview
Craneware Plc (LON:CRW), an AIM‑listed provider of financial performance software to the healthcare sector, saw its shares plunge up to 23% on Friday, touching an intraday low of 988 pence – the lowest level since 28 November 2016.
Updated Guidance
In a trading update the board revised its full‑year expectations for the year ended 30 June 2026, now forecasting revenue of $205 million to $208 million and adjusted EBITDA of $65 million to $67 million. Both ranges fall short of current market consensus.
Reason for Shortfall
The company attributed the revenue gap to the timing of eligible activity under the United States 340B drug discount programme and the deferral of certain contracts, which it expects to recognise in the subsequent financial year. Final results remain contingent on confirmation of eligible 340B activity recognised before the fiscal‑year close. The firm noted that while overall customer retention, demand and cash generation stayed strong, the final weeks of the period were materially impacted by a slower‑than‑anticipated conversion of opportunities into recognised revenue. Pharmaceutical manufacturers have expanded and operationalised restrictions on the distribution of discount‑eligible medicines, meaning Craneware records a significant portion of related revenue only after a customer completes the purchase of eligible 340B drugs, rather than at the opportunity stage. The scale of the conversion shortfall became evident only after the actual volume of 340B drugs shipped was known.
Management Commentary
Chief Executive Officer Keith Neilson said the company is “disappointed not to have delivered the growth that we expected” and highlighted that “the short‑term complexity in the pharmacy market has impacted the year, the long‑term opportunity remains intact.” He reiterated that the update reinforces the strategy of expanding beyond software and analytics into technology‑enabled operational transformation that helps customers realise savings identified by the platform, describing this as a continuing focus for innovation.
Outlook
The board views the impact as a short‑term timing issue and expects demand to continue extending beyond software into operational transformation services in future periods.